ZANTAC 150
LOE ApproachingNDAORALTABLET, EFFERVESCENT
Approved
Mar 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZANTAC 150 is an oral effervescent tablet approved in 1994 for acid-related gastrointestinal conditions. The product is a small-molecule H2-receptor antagonist, though specific indications and mechanism details are not provided in available data. It represents a mature therapeutic approach to gastric acid suppression.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity; expect declining commercial teams and focus on generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Bioavailability Study of Ranitidine Hydrochloride (Maximum Strength ZANTAC 150®) Compared to Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet (ODT) in Fasting, Healthy Male Volunteers
Started May 2009
42 enrolled
Healthy
Career Relevance
ZANTAC 150 offers limited career growth opportunities due to its approaching loss of exclusivity and mature market position. Roles focus on managing decline, executing generic transition strategy, and maximizing remaining branded revenue rather than growth initiatives.
Brand Manager
Worked on ZANTAC 150 at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.